Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Third Quarter 2020 Financial Results
Total Third Quarter R evenues of $6.6   Million Increased 29 % Y ear-over- Y ear Assigned PDUFA Goal Date of June 29, 2021   for NexoBrid BLA YAVNE, Israel , Nov. 10, 2020 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies
View HTML
Toggle Summary MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third
View HTML
Toggle Summary MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
Top-line Data is Expected in the Second Half of 2021 YAVNE, Israel , Oct. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has
View HTML
Toggle Summary MediWound Studying the Effect of EscharEx on Biofilm Burden
Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing YAVNE, Israel , Oct. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) ("MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe
View HTML
Toggle Summary MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel , Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S.
View HTML
Toggle Summary MediWound to Present at Upcoming Investor Conferences in September
YAVNE, Israel , Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , MediWound’s Chief Executive
View HTML
Toggle Summary MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
YAVNE, Israel and CAMBRIDGE, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant
View HTML
Toggle Summary MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening YAVNE, Israel , Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to
View HTML
Toggle Summary MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel , June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to
View HTML